Extended indication 2nd line hepatocellular cancer
Therapeutic value No judgement
Total cost 4,500,000.00
Registration phase Clinical trials

Product

Active substance Ramucirumab
Domain Oncology and Hematology
Main indication Liver cancer
Extended indication 2nd line hepatocellular cancer
Proprietary name Cyramza
Manufacturer Eli Lilly
Route of administration Intravenous
Therapeutical formulation Intravenous drip
Budgetting framework Intermural (MSZ)
Additional remarks Monoclonaal antilichaan gericht tegen VEGF2. Ramucirumab blokkeert de binding van VEGF aan VEGFR2 en remt zo de angiogenese.

Registration

Registration route Centralised (EMA)
Particularity Indication extension
Registration phase Clinical trials

Therapeutic value

Current treatment options Sorafenib
Therapeutic value No judgement
Duration of treatment Median 6 month / months
Frequency of administration 1 times every 2 weeks
References NCT01140347; Llovet et al. N Engl J Med 2008; 359:378-390
Additional remarks Voor Sorafenib was de mediane behandelduur ongeveer 6 maanden

Expected patient volume per year

Patient volume

< 100

Market share is generally not included unless otherwise stated.

References NKR
Additional remarks Totaal aantal patiënten in 2016 met hepatocellulair carcinoom stadium 4 betreft 158. Verwacht wordt dat ongeveer 100 patiënten hiervan in de tweede lijn zullen worden behandeld.

Expected cost per patient per year

Cost 40,000.00 - 50,000.00
References Medicijnkosten.nl
Additional remarks Flacon 100 mg Ramacirumab kost €572,39; Uitgaande van een patient van 70 kg en een behandelduur van 6 maanden komt dit neer op €41.784,43

Potential total cost per year

Total cost

4,500,000.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.